We are live on ! Find out more
LYRA

LYRA THERAPEUTICS INC

Delisted

LYRA was delisted on the 16th of March, 2026.

60 hedge funds and large institutions have $222M invested in LYRA THERAPEUTICS INC in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,600% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $27K

600% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 3

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

78% more capital invested

Capital invested by funds: $125M → $222M (+$97.1M)

36% more funds holding

Funds holding: 4460 (+16)

0.32% more ownership

Funds ownership: 1.29%1.61% (+0.32%)

Holders
60
Holders Change
+16
Holders Change %
+36.36%
% of All Funds
0.87%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
21
Reduced
3
Closed
7
Calls
$1.27M
Puts
$27K
Net Calls
+$1.24M
Net Calls Change
+$283K
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$66.8M
NCM
2
Nantahala Capital Management
Connecticut
$21.2M
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$15.7M +$10.9M +60,000 New
VPC
4
Vestal Point Capital
New York
$15.7M +$10.9M +60,000 New
Citadel Advisors
5
Citadel Advisors
Florida
$15M +$46K +254 +0.4%
SB
6
Samsara BioCapital
California
$14.6M
VA
7
VR Adviser
New York
$13.5M +$5.98M +33,029 +179%
RA
8
Rosalind Advisors
Ontario, Canada
$9.9M +$6.84M +37,774 New
PVI
9
Pura Vida Investments
New York
$7.41M
IC
10
Ikarian Capital
Texas
$6.57M
AC
11
Armistice Capital
New York
$5.7M -$1.67M -9,240 -30%
Vanguard Group
12
Vanguard Group
Pennsylvania
$5.61M +$750K +4,142 +24%
PHP
13
Parkman Healthcare Partners
Connecticut
$3.96M +$470K +2,597 +21%
WP
14
Woodline Partners
California
$3.14M +$2.17M +12,000 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.76M +$100K +555 +9%
Millennium Management
16
Millennium Management
New York
$1.71M +$227K +1,253 +24%
Ensign Peak Advisors
17
Ensign Peak Advisors
Utah
$1.58M
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$1.36M +$349K +1,931 +59%
BFM
19
Boothbay Fund Management
New York
$1.31M +$57.7K +319 +7%
Bank of America
20
Bank of America
North Carolina
$758K +$67.9K +375 +15%
BCM
21
Bridgeway Capital Management
Texas
$743K
Two Sigma Investments
22
Two Sigma Investments
New York
$695K +$421K +2,324 +709%
Citigroup
23
Citigroup
New York
$652K +$205K +1,135 +84%
CC
24
Clearline Capital
New York
$624K
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$590K +$305K +1,688 +299%

LYRA Hedge Fund Activity: Q4 2023 in Review

60 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in LYRA THERAPEUTICS INC (LYRA) for Q4 2023, worth a combined $222M — up 78% from $125M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LYRA positions and 7 closed out — a net gain of 16 holders — while 21 added to existing stakes and 3 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $10.9M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $2.32M sold.

  • 60 institutional investors held LYRA THERAPEUTICS INC (LYRA) as of Q4 2023, up from 44 in Q3 2023.
  • Funds reported $222M of LYRA THERAPEUTICS INC stock for Q4 2023, up 78% quarter-over-quarter.
  • 23 funds opened new LYRA THERAPEUTICS INC positions in Q4 2023 and 7 closed out, a net change of +16 holders.
  • The largest LYRA THERAPEUTICS INC buyer in Q4 2023 was Point72 Asset Management, an estimated $10.9M added.
  • The largest LYRA THERAPEUTICS INC seller in Q4 2023 was Soleus Capital Management, an estimated $2.32M sold.

Based on aggregated 13F filings for Q4 2023.